SAN DIEGO, April 29, 2013 /PRNewswire/ -- GenomeDx Biosciences announced today that it has expanded an existing research agreement with the Mayo Clinic. The expanded agreement includes exclusive license to certain Mayo developed intellectual property along with exclusivity covering co-developed intellectual property. The agreement also includes continued access to the clinical data concerning Mayo Clinic's cohort of prostate cancer samples to allow for longer-term follow up and evaluation of biomarkers. The initial collaboration entered in 2009 led to the development of Decipher, a transformative genomic test that forecasts risk of metastasis in men with prostate cancer. In addition, GenomeDx announced that five studies evaluating the ability of Decipher to predict metastatic prostate cancer will be featured at the 2013 American Urological Association (AUA) Annual Meeting.
"Access to the Mayo Clinic's comprehensive cohort of samples from patients classified as high risk for metastatic disease and the involvement of Mayo Clinic researchers has been essential to the development of Decipher," said Doug Dolginow, M.D., Chief Executive Officer of GenomeDx. "With Mayo Clinic's large collection of patient samples that had developed metastatic disease, we could reliably identify and validate gene sequences associated with lethal prostate cancer and to create the Decipher test."
Abstracts Related to Decipher at AUA 2013
Podium presentation (May 8, 2013, 8:00-10:00 a.m. Pacific Time)
- Validation of a genomic classifier that predicts metastatic disease progression in men with high risk pathological features post-prostatectomy, presented by R. Jeffrey Karnes, M.D., associate professor and Vice-Chair in Urology at Mayo Clinic
- Location: San Diego Convention Center, Room 1
Poster presentations (May 8, 2013, 10:30 a.m.-12:30 p.m. Pacific Time)
- Comparison of clinical and genomic models for prediction of rapid metastatic disease after radical prostatectomy, Abstract 2229; presented by Ashley Ross, M.D., Ph.D., assistant professor in the departments of urology, oncology and pathology and Johns Hopkins School of Medicine
- Performance of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy, Abstract 2240; presented by Ashley Ross, M.D., Ph.D., assistant professor in the departments of urology, oncology and pathology and Johns Hopkins School of Medicine
- Combined value of genomic biomarkers and CAPRA-S in predicting prostate cancer death in a high-risk surgical cohort, Abstract 2243; presented byMatthew Cooperberg, M.D., assistant professor of urology; epidemiology & biostatistics, University of California, San Francisco
- Evaluation of a genomic classifier for improved risk stratification in prostate cancer patients with specific adverse pathologies after surgery, Abstract 2230; presented by Doug Dolginow, M.D., CEO GenomeDx Biosciences
- All posters located in San Diego Convention Center, Room 11
Abstracts for all Decipher studies presented at AUA can be found by searching for the keyword "Decipher" at http://www.aua2013.org/abstracts/index2.cfm.
About GenomeDx Biosciences
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that have a real impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. The company's first test, Decipher, is a transformative prognostic test that provides a direct measure of the true biological risk of metastatic prostate cancer independent of PSA and other risk factors. GenomeDx is based in San Diego, California and Vancouver, British Columbia. More information is available at www.genomedx.com.
Mayo Clinic has a financial interest in technology licensed to GenomeDx.